Kinase inhibitor drugs:
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hoboken, N.J.
J. Wiley
©2009
|
| Series: | Wiley series in drug discovery and development
|
| Subjects: | |
| Online Access: | FRO01 UBG01 Volltext |
| Item Description: | Includes index Includes bibliographical references and index A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inh |
| Physical Description: | 1 Online-Ressource |
| ISBN: | 9780470524961 0470524960 9780470524954 0470524952 1282306561 9781282306561 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043390367 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2009 |||| o||u| ||||||eng d | ||
| 020 | |a 9780470524961 |9 978-0-470-52496-1 | ||
| 020 | |a 0470524960 |9 0-470-52496-0 | ||
| 020 | |a 9780470524954 |c electronic bk. |9 978-0-470-52495-4 | ||
| 020 | |a 0470524952 |c electronic bk. |9 0-470-52495-2 | ||
| 020 | |a 1282306561 |9 1-282-30656-1 | ||
| 020 | |a 9781282306561 |9 978-1-282-30656-1 | ||
| 024 | 7 | |a 10.1002/9780470524961 |2 doi | |
| 035 | |a (ZDB-35-WIC)ocn463438614 | ||
| 035 | |a (OCoLC)463438614 | ||
| 035 | |a (DE-599)BVBBV043390367 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 615/.798 |2 22 | |
| 100 | 1 | |a Li, Rongshi |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Kinase inhibitor drugs |c Rongshi Li, Jeffrey A. Stafford |
| 264 | 1 | |a Hoboken, N.J. |b J. Wiley |c ©2009 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Wiley series in drug discovery and development | |
| 500 | |a Includes index | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inh | ||
| 650 | 4 | |a Neoplasms / drug therapy | |
| 650 | 4 | |a Protein Kinase Inhibitors / therapeutic use | |
| 650 | 4 | |a Antineoplastic Agents / therapeutic use | |
| 650 | 4 | |a Drug Discovery | |
| 650 | 4 | |a Protein Kinase Inhibitors / pharmacology | |
| 650 | 4 | |a Protein Kinases / metabolism | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Protein kinases / Inhibitors / Therapeutic use | |
| 650 | 4 | |a Antineoplastic agents | |
| 700 | 1 | |a Stafford, Jeffrey A. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-470-27829-3 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-27829-1 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-27829-1 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028808951 | ||
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1804175964494626816 |
|---|---|
| any_adam_object | |
| author | Li, Rongshi |
| author_facet | Li, Rongshi |
| author_role | aut |
| author_sort | Li, Rongshi |
| author_variant | r l rl |
| building | Verbundindex |
| bvnumber | BV043390367 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn463438614 (OCoLC)463438614 (DE-599)BVBBV043390367 |
| dewey-full | 615/.798 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.798 |
| dewey-search | 615/.798 |
| dewey-sort | 3615 3798 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03053nmm a2200625zc 4500</leader><controlfield tag="001">BV043390367</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470524961</subfield><subfield code="9">978-0-470-52496-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470524960</subfield><subfield code="9">0-470-52496-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470524954</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-470-52495-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470524952</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-470-52495-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1282306561</subfield><subfield code="9">1-282-30656-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781282306561</subfield><subfield code="9">978-1-282-30656-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/9780470524961</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn463438614</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)463438614</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043390367</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.798</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Rongshi</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Kinase inhibitor drugs</subfield><subfield code="c">Rongshi Li, Jeffrey A. Stafford</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">J. Wiley</subfield><subfield code="c">©2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Wiley series in drug discovery and development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinase Inhibitors / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinase Inhibitors / pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinases / metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein kinases / Inhibitors / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stafford, Jeffrey A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-470-27829-3</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-27829-1</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-27829-1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028808951</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043390367 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:24:39Z |
| institution | BVB |
| isbn | 9780470524961 0470524960 9780470524954 0470524952 1282306561 9781282306561 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028808951 |
| oclc_num | 463438614 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | J. Wiley |
| record_format | marc |
| series2 | Wiley series in drug discovery and development |
| spelling | Li, Rongshi Verfasser aut Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford Hoboken, N.J. J. Wiley ©2009 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Wiley series in drug discovery and development Includes index Includes bibliographical references and index A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inh Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism MEDICAL / Pharmacology bisacsh Medizin Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents Stafford, Jeffrey A. Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 0-470-27829-3 Erscheint auch als Druck-Ausgabe, Hardcover 978-0-470-27829-1 https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Li, Rongshi Kinase inhibitor drugs Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism MEDICAL / Pharmacology bisacsh Medizin Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents |
| title | Kinase inhibitor drugs |
| title_auth | Kinase inhibitor drugs |
| title_exact_search | Kinase inhibitor drugs |
| title_full | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_fullStr | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_full_unstemmed | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_short | Kinase inhibitor drugs |
| title_sort | kinase inhibitor drugs |
| topic | Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism MEDICAL / Pharmacology bisacsh Medizin Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents |
| topic_facet | Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism MEDICAL / Pharmacology Medizin Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9780470524961 |
| work_keys_str_mv | AT lirongshi kinaseinhibitordrugs AT staffordjeffreya kinaseinhibitordrugs |